Traitement Anti-inflammatoire en Pédiatrie (CHU Sétif)

Abstract

he use of anti-inflammatory drugs in pediatrics has a complex and evolving history, shaped by medical advancements, concerns about drug safety, and the specific needs of children. We conducted a retrospective and descriptive epidemiological study to evaluate the use of antiinflammatory drugs on a sample of 1200 patients hospitalized in the pediatric and neonatology departments at the CHU of Sétif (200 patients admitted to neonatology; 1000 patients admitted to pediatrics) during the period going from December 1, 2023, to April 30, 2024. We used 1200 prescriptions as well as the medical records of hospitalized patients as data collection tools. The results obtained are: • 15% of patients admitted to neonatology have an inflammatory condition ; • 21% of patients admitted to pediatrics have an inflammatory condition ; • 4% of anti-inflammatory drugs are used in neonatology : 100% corticosteroids, 0% nonsteroidal anti-inflammatory drugs (NSAIDs) ; • 22% of anti-inflammatory drugs are used in pediatrics : 100% corticosteroids, 0% NSAIDs; • Corticosteroids used in neonatology: Dexamethasone (56%), Budesonide (33%), Prednisolone (11%) • Corticosteroids used in pediatrics: Dexamethasone (16%), Budesonide (14%), HHC (4%), Prednisolone (1%). This study highlights the importance of thoughtful and careful prescription of anti-inflammatory drugs in pediatrics to ensure safe and effective care, just as it is for adults.